Rege Nephro Co. raised 22.5 billion yen in a Series B funding led by DCI Partners to advance clinical trials for its kidney disease treatment RN-014.
Amount Raised
¥22.5 Billion
Round Type
Series B
KyotoBiotechnologyHealth CareTherapeuticsInvestors
Description
Rege Nephro Co., Ltd. closed its Series B funding round, raising 22.5 billion yen of a planned 25 billion yen. The round included strategic investors like DCI Partners, aimed at advancing clinical trials for treatments of kidney diseases.
Quick answer
Rege Nephro Ltd raised ¥22.5 Billion in a Series B round, dated October 7, 2024. Investors: I Lab Cvc1, Asahi Kasei, Toyo Seikan Group Holdings, Senshu Ikeda Capital Co., Chushin Venture Capital Co., Screen Holdings Co., Shimadzu and Industrial Technology Investment. Rege Nephro Ltd is based in Kyoto, Kyoto Prefecture, Japan.
- How much did Rege Nephro Ltd raise?
- Rege Nephro Ltd raised ¥22.5 Billion in a Series B round on October 7, 2024.
- Who invested in Rege Nephro Ltd?
- I Lab Cvc1, Asahi Kasei, Toyo Seikan Group Holdings, Senshu Ikeda Capital Co., Chushin Venture Capital Co., Screen Holdings Co., Shimadzu and Industrial Technology Investment are named as investors in this round.
- What does Rege Nephro Ltd do?
- Rege Nephro, founded in 2019, is a clinical-stage biotech company leveraging technology based on research of Prof.
- Where is Rege Nephro Ltd based and how big is it?
- Rege Nephro Ltd is based in Kyoto, Kyoto Prefecture, Japan. Fundz records about 16 employees.
- Who are the decision-makers at Rege Nephro Ltd?
- Fundz holds 3 contacts at Rege Nephro Ltd, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Rege Nephro Ltd that raised within 45 days of this round, from Fundz verified event records.
- Biofrontera raised $4.2M (Seed) on November 21, 2024.
- Intensity Therapeutics raised $3.6M (Seed) on November 21, 2024.
- Debiopharm raised $5.8M (Funding Round) on November 21, 2024.
- HCW Biologics raised $6.9M on November 20, 2024.
- Adipo Therapeutics raised $4.7M (Seed) on November 19, 2024.
- Qualigen Therapeutics raised $5.1M on November 18, 2024.
Who to call at Rege Nephro Ltd, and when
A new round usually means Rege Nephro Ltd is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Rege Nephro Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rege Nephro Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rege Nephro Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rege Nephro Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRege Nephro Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.